Q3 Revenue Falls to $7.9M, Cash Drops to $12.5M as 2026 Guidance Is Cut
BHST sits 22% above its 52-week low of $1.371 on light trading volume (0.3× avg).
Summary
Q3 2026 revenue came in at $7.9 million, down from $9.1 million a year ago and $8.8 million in Q2, as BioHarvest deliberately pulled back on lower-return VINIA customer acquisition. Gross margin compressed to 54% from roughly 61% a year ago on a mix shift away from higher-margin CDMO development revenue, and the operating loss widened to $3 million from $0.9 million. Cash and bank deposits fell to $12.5 million at September 30 from $16.2 million at June 30 and $23 million at year-end 2025 — a burn rate that matters for a company this size. Management cut full-year 2026 revenue guidance to $32-$33.5 million with an Adjusted EBITDA loss of $5.5-$7.5 million, revising VINIA D2C to $31-$32 million and CDMO to just $1-$1.5 million with a $4-$5 million EBITDA loss. The offsetting item is the 20-ton plant-based fragrance supply agreement, which the company estimates will generate $20-$30 million of revenue in 2027-2028, with limited production possibly starting as early as Q1 2027. Management says the VINIA marketing changes should show benefits beginning in Q1 2027; the 8:00 a.m. ET call today will be the first chance to press on the cash runway and the fragrance program timeline.
At the time of this announcement, BHST was trading at $1.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.7M. The 52-week trading range was $1.37 to $8.30. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: TMX Newsfile.